ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $3.50.

A number of research analysts recently weighed in on ALXO shares. Jefferies Financial Group assumed coverage on shares of ALX Oncology in a report on Thursday, November 13th. They issued a “buy” rating and a $4.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALX Oncology in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded ALX Oncology from a “sell” rating to a “hold” rating in a report on Monday, December 22nd.

Institutional Trading of ALX Oncology

A number of large investors have recently made changes to their positions in the company. Ameriprise Financial Inc. acquired a new stake in ALX Oncology in the third quarter valued at approximately $1,195,000. Jane Street Group LLC acquired a new stake in shares of ALX Oncology in the 2nd quarter valued at $84,000. Acadian Asset Management LLC lifted its position in shares of ALX Oncology by 16.8% during the 1st quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock worth $806,000 after purchasing an additional 186,883 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of ALX Oncology by 26.9% during the third quarter. Two Sigma Investments LP now owns 606,671 shares of the company’s stock worth $1,110,000 after purchasing an additional 128,737 shares in the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of ALX Oncology by 183.6% during the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock worth $74,000 after purchasing an additional 77,065 shares in the last quarter. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

ALX Oncology Trading Down 3.4%

Shares of NASDAQ ALXO opened at $1.68 on Tuesday. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $91.09 million, a PE ratio of -0.83 and a beta of 0.51. ALX Oncology has a twelve month low of $0.40 and a twelve month high of $2.27. The stock has a fifty day simple moving average of $1.37 and a 200-day simple moving average of $1.28.

ALX Oncology (NASDAQ:ALXO) last announced its earnings results on Friday, November 7th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.04). On average, equities analysts forecast that ALX Oncology will post -2.76 earnings per share for the current year.

ALX Oncology Company Profile

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.